Department of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Shanghai, China.
Department of Nephrology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Semin Cancer Biol. 2022 Nov;86(Pt 2):607-623. doi: 10.1016/j.semcancer.2022.03.016. Epub 2022 Mar 23.
Although the survival rate of hematological malignancies (HM) has increased in recent years, the unnecessary adverse effect to the body is usually generated by the traditional chemotherapy for HM due to the lack of specificity to tumor tissue. Nanodrug delivery systems have exhibited unique advantages in targetability, stability and reducing toxicity, attracting wide concern, which is expected to be the prevalent alternative for the treatment of HM. In this review, we systemically introduced the current therapeutic strategies and the categories of HM. Subsequently, five key factors including circulation, targeting, penetration, internalization and release involving in tailoring nanoparticles were demonstrated, followed by the introduction of the development of nanodrug delivery-traditional synthetic nanomaterilas, biomimetic cell membrane coating nanomaterials, cell-based nanomaterials as well as immunotherapy combined with nanodrug. Afterwards, the recent advances of nanodrug delivery system for the treatment of HM were introduced. Moreover, the challenge and prospect of nanodrug delivery system in treating HM were discussed. The promising drug delivery system will provide new therapeutic avenues for the treatment of HM.
虽然近年来血液系统恶性肿瘤（HM）的生存率有所提高，但由于对肿瘤组织缺乏特异性，传统的 HM 化疗通常会产生不必要的身体不良反应。纳米药物递送系统在靶向性、稳定性和降低毒性方面表现出独特的优势，引起了广泛的关注，有望成为治疗 HM 的主流替代品。在这篇综述中，我们系统地介绍了目前的治疗策略和 HM 的分类。随后，展示了涉及定制纳米颗粒的五个关键因素，包括循环、靶向、渗透、内化和释放，随后介绍了纳米药物递送的发展-传统合成纳米材料、仿生细胞膜包覆纳米材料、基于细胞的纳米材料以及免疫疗法与纳米药物的结合。之后，介绍了纳米药物递送系统治疗 HM 的最新进展。此外，还讨论了纳米药物递送系统在治疗 HM 中的挑战和前景。有前途的药物递送系统将为 HM 的治疗提供新的治疗途径。
